Analysis of Gene Therapy market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
The global gene therapy market size was valued at US$ 1.55 Billion in 2021. The market is projected to grow from US$ 1.85 Billion in 2022 to US$ 10.1 Billion by 2032, exhibiting a CAGR of 18.5% during the forecast period.
The world has witnessed a significant increase in the number of cases of rare diseases, which has fueled the demand for cell and gene therapy. Ex-vivo gene therapy is becoming more popular for neurological treatments, which is expected to drive gene therapy market growth through 2032.
Anticipated Base Year Value (2021)
US$ 1.55 Billion
Expected Market Value (2022)
US$ 1.85 Billion
Projected Forecast Value (2032)
US$ 10.1 Billion
Global Growth Rate (2022-2032)
Expected Growth Rate of the Asia-Pacific (2022-2032)
Key Gene Therapy Providers
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Over the last few years, the world has seen a significant increase in focus on health care, which has resulted in a massive increase in research and development activities. The rising prevalence of rare diseases has also increased the demand for novel treatments, which has driven gene therapy market potential in the past. A CAGR of 18.7% was recorded for the market from 2015 to 2021.
The increasing use of gene modification in a variety of treatments, as well as the increasing use of genome editing in biotechnology applications, are also expected to guide the gene therapy market in the coming years. The global gene therapy industry is expected to be hampered by high gene therapy costs and a lack of standardization. From 2022 to 2032, demand for gene therapies is expected to grow at an astronomical CAGR of 18.5%.
The presence of companies offering exclusive lentivector platforms is hastening revenue growth in this segment. Oxford Biomedica Plc, for example, has an exclusive lentivector platform, an advanced and safe gene delivery system capable of carrying payloads of up to 9kb and capable of permanent modification of dividing and nondividing cells while requiring no pre-existing immunity.
Research and development (R&D) activities are also expected to have a significant impact on the market. Several companies are aiming to build a gene therapy platform with a strategy centered on establishing a transformational portfolio through in-house capabilities and enhancing those capabilities through strategic collaborations, R&D expansion, and potential licensing, merger, and acquisition activities.
For example, the Cystic Fibrosis Foundation announced an investment in SalioGen Therapeutics in January 2022 to support the company's preclinical research into novel gene therapy for cystic fibrosis. SalioGen's Gene Coding approach is intended to activate, deactivate, or modify the function of any gene in the genome.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Gene therapies are expensive medical procedures that necessitate significant capital investment on the part of both the provider and the patient, which limits the global gene therapy market's growth.
Gene modifications necessitate precision equipment, which significantly raises the cost of cell and gene therapy and limits the global adoption of these therapies. Due to high costs and low adoption, viral vector gene therapies are expected to grow at the slowest rate.
With a revenue share of more than 56% in 2022, the North American regional market will lead the industry and will grow at the fastest CAGR over the forecast years. Several government agencies are investing in the region because of a strong regulatory framework for promoting the development of cellular therapy and the presence of a large number of biopharma companies.
This, in turn, is propelling the regional market forward. The presence of centers and institutes engaged in gene therapy research and development is expected to drive the market in North America.
Also, the rising prevalence of chronic diseases, rising healthcare expenditure, the presence of advanced healthcare infrastructure, and the availability of reimbursements are also major factors driving the market growth. The approval of Zolgensma in 2019 has, on the other hand, greatly favored the US market. Despite the price controversies, the product is expected to have profitable revenue growth in the forecast period.
The Asia-Pacific (APAC) gene therapy market was valued at US$ 351 Million in 2021, with a CAGR of 18.3%. This is accomplished through the optimization of vectors such as retroviruses and lentiviruses, the introduction of new techniques such as induced pluripotent stem cells in conjunction with current gene editing models, and even trials in germ cells.
The focus on healthcare in India has increased, and this trend is expected to drive gene therapy demand over the forecast period. The country is also seeing an increase in cancer cases, which is encouraging the use of gene therapy in oncology treatments. The key players in the APAC gene therapy market include Novartis AG, Sibiono GeneTech Co. Ltd., Shanghai Sunway Biotech Co. Ltd., Kolon Life Science Inc., AnGes Inc., and Amgen Inc.
During the period 2022-2032, the European gene therapy market is expected to grow at a CAGR of more than 19%. The European market is the best for manufacturing cell and gene therapy products. Europe is home to more than 238 regenerative medicine companies. Europe is home to nearly a quarter of the world's regenerative medicine therapeutic developers.
In 2020, the oncology segment accounted for 31% of the European cell and gene therapy market. Currently, over 61 companies in Europe are specializing in cell therapy and introducing cell therapy products. Some key players in the Europe market are Novartis, Spark Therapeutics, Amgen, Gilead Sciences and Organogenesis.
Don't Need a Global Report?
Save 40% on Country & Region specific reports
The cancer segment is expected to account for a sizable portion of the market. The increasing burden of cancer disorder, the growing emphasis on research to develop an effective cancer treatment, and rising cancer research investments are all factors driving the segment growth.
According to Globocan 2020, an estimated 19,292,789 new cancer cases and 9,958,133 cancer deaths were reported worldwide in 2020. Various gene therapy strategies are currently being used in the treatment of cancer. These include anti-angiogenic gene therapy, pro-drug activating suicide gene therapy, immune modulation based on gene therapy, oncolytic virotherapy, gene defect correction/compensation, antisense, genetic manipulation of apoptotic and tumor invasion pathways, and RNAi strategies.
These therapies have targeted cancer types such as lung, brain, breast, pancreatic, liver, colorectal, prostate, bladder, head and neck, skin, renal and ovarian cancer.
Yescarta received FDA approval for the treatment of diffuse large B-cell lymphoma (DLBCL) in adults, significantly increasing its market share. This therapy is expected to have a market share of more than 44.5% in the global gene therapy industry landscape. Luxturna-based gene therapies are expected to grow rapidly over the forecast period, with a market share of more than 36% by 2032.
The global gene therapy market is fiercely competitive, with only a few major players. Companies like Amgen Inc., Bluebird Bio, Gilead Sciences, Inc., Novartis AG, Orchard Therapeutics, Sibiono GeneTech Co. Ltd., Spark Therapeutics (Roche AG), and UniQure N.V., have a sizable market share in the Gene Therapy market. To secure a position in the global market, various strategic alliances such as collaborations, acquisitions, and the launch of advanced products have been formed.
- Premium Report Details -
- Let's Connect -
- Quick Contact -
- Get Started -
Get insights that lead to new growth opportunitiesBuy Now
Get A Special pricing for start-ups and universitiesEnquiry Before Buying
- Humble, Yet Honored -
- Research Methodology -
An Adaptive Approach to Modern-day Research NeedsGet Methodology
- Related Reports -
Demand for gene therapy to reach US$ 1.85 Billion in 2022
From 2022-2032, gene therapy demand is likely to surge at an 18.5% CAGR
By 2032, the market for gene therapy is likely to be valued at US$ 10.1 Billion
As per Fact.MR, North America will likely yield 56% of global gene therapy market revenue in 2022
The APAC gene therapy industry is forecast to flourish at a CAGR of 18.3% from 2022-2032
In Europe, the gene therapy market is expected to document a CAGR exceeding 19% until 2032
According to Fact.MR, the gene therapy market was valued at US$ 1.55 Billion in 2021
From 2015-2021, Fact.MR estimated the gene therapy industry to have expanded at a CAGR of 18.7%
Need An Exclusive Report For Your Unique Requirement?